ATP6V0A4

ATP6V0A4 encodes the a4 isoform of the V0 sector of the vacuolar H⁺-ATPase (V-ATPase), which localizes to the apical compartment of intercalated cells throughout the kidney collecting duct, connecting segment, distal convoluted tubule, loop of Henle, and proximal tubule (S1/S2), where it mediates electrogenic proton secretion required for urinary acidification (PMID:14638902). Under acid-loading or potassium depletion, a4 undergoes subcellular redistribution to the apical membrane without changes in total protein expression, indicating that V-ATPase activity is regulated by trafficking rather than transcriptional control (PMID:14638902). Loss-of-function mutations in ATP6V0A4 cause autosomal recessive distal renal tubular acidosis (rdRTA), with some patients developing late-onset sensorineural hearing loss; disease-causing missense mutations destabilize the protein via proteasomal degradation and ER retention (e.g., R449H) or block the proton translocation pathway while preserving protein stability and trafficking (e.g., G820R) (PMID:12414817, PMID:29311258).

1. 1999 High

   Establishing that rdRTA with normal hearing maps to a distinct locus on 7q33-34, separate from ATP6V1B1, predicted the existence of a second V-ATPase gene (later identified as ATP6V0A4) causing distal renal tubular acidosis.

   Evidence Genome-wide linkage analysis with LOD score 8.84 across 13 kindreds with molecular exclusion of ATP6B1

   PMID:10577919

   Open questions at the time

   • The causative gene at the 7q33-34 locus was not yet identified
   • Whether the mapped gene encoded a V-ATPase subunit was unknown
2. 2002 High

   Identification of ATP6V0A4 mutations as the cause of rdRTA with preserved hearing resolved the 7q34 locus and revealed unexpected expression in the human cochlea, explaining late-onset hearing loss in some patients.

   Evidence Mutation screening in rdRTA kindreds, RT-PCR of human inner ear tissue

   PMID:12414817

   Open questions at the time

   • Precise subcellular localization of a4 along the nephron was unresolved
   • Mechanism by which mutations cause disease (protein stability vs. function) was unknown
3. 2003 High

   Detailed nephron mapping showed a4 localizes apically across multiple nephron segments and demonstrated that acid-base regulation of V-ATPase occurs through a4 subcellular redistribution rather than changes in protein abundance, establishing a trafficking-based regulatory mechanism.

   Evidence Immunohistochemistry, Western blotting, and RT-PCR on dissected nephron segments; NH4Cl acid-loading and K⁺ depletion in mice

   PMID:14638902

   Open questions at the time

   • The molecular signals and machinery directing a4 apical trafficking remain unidentified
   • Whether other V-ATPase subunits co-traffic with a4 was not tested
4. 2012 Medium

   Detection of ectopic ATP6V0A4 expression in specific glioma subtypes, associated with a 7q34 tandem duplication, raised the possibility that a4 may contribute to tumor biology outside its normal renal and cochlear expression domains.

   Evidence RT-PCR/qPCR of 205 glioma biopsies with chromosomal analysis

   PMID:22460948

   Open questions at the time

   • No functional experiments tested whether a4 expression contributes to glioma biology
   • Whether ectopic a4 assembles into functional V-ATPase complexes in glioma cells is unknown
5. 2018 High

   Biochemical dissection of disease-causing missense mutations revealed two distinct pathomechanisms: R449H causes protein instability with proteasomal degradation and ER retention, while G820R preserves stability but is predicted to block the proton translocation pathway, providing the first mechanistic classification of ATP6V0A4 mutations.

   Evidence Cycloheximide chase, co-immunoprecipitation, immunofluorescence, endoglycosidase assays, and 3D molecular modeling of FLAG-tagged a4 variants in HEK293 cells

   PMID:29311258

   Open questions at the time

   • Proton translocation blockade by G820R was inferred from modeling, not measured directly
   • Whether ER-retained R449H mutant can be pharmacologically rescued is untested
   • Role of VMA21 assembly factor in normal a4 biogenesis versus mutant retention is not fully defined
6. 2021 Medium

   Demonstration that multiple exonic ATP6V0A4 variants disrupt pre-mRNA splicing through ESE/ESS modulation expanded the mutational spectrum and revealed that apparently synonymous or missense variants can be pathogenic through splicing rather than protein-level effects.

   Evidence Minigene splicing assays with bioinformatic ESE/ESS prediction

   PMID:34157794

   Open questions at the time

   • Splicing defects were shown in minigene context, not confirmed in patient-derived cells
   • Whether partial exon skipping produces any residual functional protein is unknown

• The molecular signals that trigger a4 apical trafficking in response to acid-base perturbation, the structural basis of proton translocation through a4, and whether pharmacological chaperones can rescue ER-retained mutants remain unresolved.
• No high-resolution structure of a4 is available
• Trafficking adaptors or kinases regulating a4 redistribution have not been identified
• Functional role of ectopic a4 in glioma has not been tested